"GSK needs to replace Avandia and now Takeda may need to replace Actos."
"I think Takeda would have the inside tract on acquiring or partnering with Xoma because of their current relationship."
"Let the bidding begin."
This is overdue for substantially good news.
The orphan drug news bounced it 50%. It's tremendously oversold and cheap here.
Partnership news triples the share price.
p.s. 52 week high was over $15.00
No wonder Xoma's management seemed so confident in the last conference call in regards to finding a partner. Takeda's management had to know this was coming.
Might be time to add a few cheap shares at the open tomorrow.